Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (277) 277
Publication (20) 20
Patent (10) 10
Conference Proceeding (2) 2
Book / eBook (1) 1
Book Chapter (1) 1
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (102) 102
adult (73) 73
index medicus (73) 73
middle aged (73) 73
male (71) 71
hematology (66) 66
female (65) 65
aged (51) 51
oncology (33) 33
treatment outcome (31) 31
adolescent (27) 27
aged, 80 and over (23) 23
cancer (22) 22
transplantation (22) 22
analysis (21) 21
young adult (21) 21
care and treatment (19) 19
chemotherapy (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
chronic myeloid leukemia (17) 17
leukemia (17) 17
multiple myeloma (15) 15
risk factors (15) 15
stem cells (15) 15
therapy (15) 15
disease-free survival (14) 14
hematopoietic stem cell transplantation (14) 14
antineoplastic agents - therapeutic use (13) 13
diagnosis (13) 13
hematopoietic stem cells (13) 13
research (13) 13
child (12) 12
recurrence (12) 12
survival (12) 12
survival analysis (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
genetic aspects (11) 11
immunology (11) 11
leukemia, lymphocytic, chronic, b-cell - drug therapy (11) 11
nilotinib (11) 11
remission induction (11) 11
rituximab (11) 11
actuating-floats (10) 10
blasting (10) 10
cocks (10) 10
devices for venting or aerating (10) 10
engineering elements and units (10) 10
follow-up studies (10) 10
general measures for producing and maintaining effectivefunctioning of machines or installations (10) 10
heating (10) 10
hematology, oncology and palliative medicine (10) 10
imatinib (10) 10
lighting (10) 10
mechanical engineering (10) 10
medicine, general & internal (10) 10
patients (10) 10
relapse (10) 10
taps (10) 10
thermal insulation in general (10) 10
treatment (10) 10
valves (10) 10
weapons (10) 10
cladribine (9) 9
hemic and lymphatic diseases (9) 9
medical colleges (9) 9
retrospective studies (9) 9
abridged index medicus (8) 8
chronic myelogenous leukemia (8) 8
dasatinib (8) 8
dose-response relationship, drug (8) 8
medicine & public health (8) 8
prognosis (8) 8
trial (8) 8
antimitotic agents (7) 7
antineoplastic agents (7) 7
bone marrow (7) 7
chronic lymphocytic leukemia (7) 7
cladribine - administration & dosage (7) 7
clinical trials (7) 7
disease (7) 7
drug administration schedule (7) 7
efficacy (7) 7
fludarabine (7) 7
hypereosinophilic syndrome (7) 7
imatinib mesylate (7) 7
lymphoma (7) 7
medical and health sciences (7) 7
medicin och hälsovetenskap (7) 7
medicine (7) 7
multicenter (7) 7
mutation (7) 7
pharmacokinetics (7) 7
prospective studies (7) 7
pyrimidines - therapeutic use (7) 7
thalidomide (7) 7
time factors (7) 7
toxicity (7) 7
antibodies, monoclonal - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
article (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients
by Nowak, Jacek and Kościńska, Katarzyna and Mika‐Witkowska, Renata and Rogatko‐Koroś, Marta and Mizia, Sylwia and Jaskuła, Emilia and Polak, Małgorzata and Mordak‐Domagała, Monika and Lange, Janusz and Gronkowska, Anna and Jędrzejczak, Wiesław Wiktor and Kyrcz‐Krzemień, Sławomira and Markiewicz, Mirosław and Dzierżak‐Mietła, Monika and Tomaszewska, Agnieszka and Nasiłowska‐Adamska, Barbara and Szczepiński, Andrzej and Hałaburda, Kazimierz and Hellmann, Andrzej and Komarnicki, Mieczysław and Gil, Lidia and Czyż, Anna and Wachowiak, Jacek and Barańska, Małgorzata and Kowalczyk, Jerzy and Drabko, Katarzyna and Goździk, Jolanta and Wysoczańska, Barbara and Bogunia‐Kubik, Katarzyna and Graczyk‐Pol, Elżbieta and Witkowska, Agnieszka and Marosz‐Rudnicka, Anna and Nestorowicz, Klaudia and Dziopa, Joanna and Szlendak, Urszula and Warzocha, Krzysztof and Lange, and Andrzej and Polish Donor-Recipient Matching and Polish Donor-Recipient Matching Study Group
American Journal of Hematology, ISSN 0361-8609, 10/2014, Volume 89, Issue 10, pp. E176 - E183
Among cancers treated with allogeneic hematopoietic stem‐cell transplantation (HSCT), some are sensitive to natural killer (NK) cell reactivity, described as... 
ALLOREACTIVITY | NATURAL-KILLER-CELLS | ACTIVATION | POLISH POPULATION | RECOGNITION | MISSING SELF | HLA-B | IG-LIKE RECEPTORS | LEUKEMIA | KIR-LIGAND INCOMPATIBILITY | HEMATOLOGY | Acute Disease | Killer Cells, Natural | Humans | Histocompatibility Antigens Class I - immunology | Child, Preschool | Donor Selection - methods | Hematopoietic Stem Cell Transplantation | Genotype | Infant | Male | Graft vs Host Disease - immunology | Neoplasms - therapy | Allografts | Neoplasms - immunology | Adolescent | Adult | Female | Graft vs Host Disease - prevention & control | Unrelated Donors | Neoplasms - pathology | Child | Receptors, KIR - immunology | Killer cells | Transplantation | Analysis | Hematopoietic stem cells | Stem cells | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes
by Valent, Peter, MD and Klion, Amy D., MD and Horny, Hans-Peter, MD and Roufosse, Florence, MD, PhD and Gotlib, Jason, MD and Weller, Peter F., MD and Hellmann, Andrzej, MD and Metzgeroth, Georgia, MD and Leiferman, Kristin M., MD and Arock, Michel, PharmD, PhD and Butterfield, Joseph H., MD and Sperr, Wolfgang R., MD and Sotlar, Karl, MD and Vandenberghe, Peter, MD, PhD and Haferlach, Torsten, MD and Simon, Hans-Uwe, MD, PhD and Reiter, Andreas, MD and Gleich, Gerald J., MD
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2012, Volume 130, Issue 3, pp. 607 - 612.e9
Eosinophilia is an important indicator of various neoplastic and nonneoplastic conditions. Depending on the underlying disease and mechanisms, eosinophil... 
Allergy and Immunology | eosinophilic leukemia | hypereosinophilia of undetermined significance | classification | criteria | Hypereosinophilic syndrome | CHURG-STRAUSS-SYNDROME | TYROSINE KINASE | GASTROINTESTINAL-TRACT | IMMUNOLOGY | CHRONIC MYELOPROLIFERATIVE DISEASES | SYSTEMIC MASTOCYTOSIS | GROWTH-FACTOR RECEPTOR | FAMILIAL EOSINOPHILIA | EPISODIC ANGIOEDEMA | ALLERGY | IDIOPATHIC HYPEREOSINOPHILIC SYNDROME | FIP1L1-PDGFRA FUSION | Terminology as Topic | Eosinophils - physiology | Hypereosinophilic Syndrome - classification | Eosinophilia - classification | Humans | Eosinophilia - diagnosis | Allergy | Medical colleges | Platelet-derived growth factor | Parasitic diseases | Analysis | Leukemia | Fibroblast growth factors | Allergic reaction | Public health | Lymphatic system | Disease | Cytokines | Genes | Stem cells | Classification | Thrombosis | Chromosomes | Tumors | Defects | Clinical trials | Conferences | Eosinophilia | Hypersensitivity | Leukocytes (eosinophilic) | Life Sciences | Immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Aktualna pozycja oraz przyszłość medycyny wewnȩtrznej - Głos w dyskusji
by Hellmann, Andrzej
Polskie Archiwum Medycyny Wewnetrznej, ISSN 0032-3772, 2016, Volume 126, Issue 12, pp. 1054 - 1057
Journal Article
Details down arrow
4. Full Text Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
by Tadeusz Robak and Krzysztof Jamroziak and Joanna Gora-Tybor and Beata Stella-Holowiecka and Lech Konopka and Bernadetta Ceglarek and Krzysztof Warzocha and Ilona Seferynska and Jarosław Piszcz and Malgorzata Calbecka and Aleksandra Kostyra and Jadwiga Dwilewicz-Trojaczek and Anna Dmoszyñska and Krystyna Zawilska and Andrzej Hellmann and Andrzej Zdunczyk and Stanislaw Potoczek and Magdalena Piotrowska and Krzysztof Lewandowski and Jerzy Z. Blonski
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 11, pp. 1863 - 1869
Purpose Little is known about comparison of the activity of different purine nucleoside analogs in chronic lymphocytic leukemia (CLL). We conducted a... 
TRIAL | CELLS | MULTICENTER | PREDNISONE | GENE | ONCOLOGY | RESISTANCE | PURINE ANALOGS | CHLORAMBUCIL | REMISSION | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Immunophenotyping | Male | Survival Rate | Treatment Outcome | Vidarabine - analogs & derivatives | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Remission Induction | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Cladribine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Vidarabine - administration & dosage | Cytogenetic Analysis | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
by Burger, Jan A and Tedeschi, Alessandra and Barr, Paul M and Robak, Tadeusz and Owen, Carolyn and Ghia, Paolo and Bairey, Osnat and Hillmen, Peter and Bartlett, Nancy L and Li, Jianyong and Simpson, David and Grosicki, Sebastian and Devereux, Stephen and McCarthy, Helen and Coutre, Steven and Quach, Hang and Gaidano, Gianluca and Maslyak, Zvenyslava and Stevens, Don A and Janssens, Ann and Offner, Fritz and Mayer, Jiří and O’Dwyer, Michael and Hellmann, Andrzej and Schuh, Anna and Siddiqi, Tanya and Polliack, Aaron and Tam, Constantine S and Suri, Deepali and Cheng, Mei and Clow, Fong and Styles, Lori and James, Danelle F and Kipps, Thomas J and RESONATE-2 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2425 - 2437
The Bruton's tyrosine kinase inhibitor ibrutinib was compared with the alkylating agent chlorambucil in patients with chronic lymphocytic leukemia. Ibrutinib... 
MEDICINE, GENERAL & INTERNAL | CLL | CYCLOPHOSPHAMIDE | TYROSINE KINASE | RITUXIMAB | OPEN-LABEL | CHLORAMBUCIL | FLUDARABINE | CANCER | PREVIOUSLY UNTREATED PATIENTS | OBINUTUZUMAB | Pyrazoles - therapeutic use | Chlorambucil - adverse effects | Chlorambucil - therapeutic use | Humans | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Diarrhea - chemically induced | Disease-Free Survival | Antineoplastic Agents - adverse effects | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Female | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Neutropenia - chemically induced | Pyrazoles - adverse effects | Clinical trials | Treatment outcome | Usage | Lymphocytic leukemia | Drug therapy | Analysis | Chronic lymphatic leukemia | Leukemia | Diarrhea | Fatigue | Nausea | Lymphatic leukemia | Lymphoma | Hemorrhage | Survival | Cough | Chlorambucil | Immunosuppression | Chemotherapy | Vomiting | Immunotherapy | Hemoglobin | Myelosuppression | Neutropenia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. The current status and the future of internal medicine: a voice in the discussion
by Hellmann, A
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, ISSN 0032-3772, 2016, Volume 126, Issue 12, pp. 1054 - 1057
MEDICINE, GENERAL & INTERNAL | Specialization | Internal Medicine - trends | Humans | Internal Medicine - manpower
Journal Article
Details down arrow
7. Full Text Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
by William G. Wierda and Thomas J. Kipps and Jiří Mayer and Stephan Stilgenbauer and Cathy D. Williams and Andrzej Hellmann and Tadeusz Robak and Richard R. Furman and Peter Hillmen and Marek Trneny and Martin J.S. Dyer and Swami Padmanabhan and Magdalena Piotrowska and Tomas Kozak and Geoffrey Chan and Randy Davis and Nedjad Losic and Joris Wilms and Charlotte A. Russell and Anders Österborg and Hx-CD20-406 Study Investigators
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 10, pp. 1749 - 1755
Purpose New treatments are needed for patients with fludarabine-and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with... 
SURVIVAL | ALEMTUZUMAB | PLUS CYCLOPHOSPHAMIDE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | ONCOLOGY | RITUXIMAB THERAPY | ANTI-CD20 ANTIBODY | FOLLICULAR LYMPHOMA | PATIENT | PHASE-II MULTICENTER | MONOCLONAL-ANTIBODIES | Antigens, CD20 - immunology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Disease-Free Survival | Aged, 80 and over | Adult | Female | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Hema7 | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
by Dimopoulos, Meletios and Spencer, Andrew and Attal, Michael and Prince, H. Miles and Harousseau, Jean-Luc and Dmoszynska, Anna and Miguel, Jesus San and Hellmann, Andrzej and Facon, Thierry and Foà, Robin and Corso, Alessandro and Masliak, Zvenyslava and Olesnyckyj, Marta and Yu, Zhinuan and Patin, John and Zeldis, Jerome B and Knight, Robert D and Multiple Myeloma 010 Study and Multiple Myeloma Study Investigators
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 21, pp. 2123 - 2132
Thalidomide has activity in multiple myeloma, but its use is limited by a constellation of adverse effects, most notably peripheral neuropathy. Lenalidomide,... 
CELLS | MEDICINE, GENERAL & INTERNAL | THERAPY | ANALOGS | DRUG-RESISTANCE | THALIDOMIDE | COMBINATION | Thalidomide - adverse effects | Recurrence | Glucocorticoids - therapeutic use | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Disease Progression | Thalidomide - analogs & derivatives | Dexamethasone - therapeutic use | Multiple Myeloma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Thalidomide - therapeutic use | Drug Therapy, Combination | Immunologic Factors - therapeutic use | Dexamethasone | Drug therapy, Combination | Drug therapy | Comparative analysis | Health aspects | Multiple myeloma | Bone marrow | Chemotherapy | Transplants & implants | Medical treatment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Role of Donor Activating KIR–HLA Ligand–Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients
by Nowak, Jacek and Kościńska, Katarzyna and Mika-Witkowska, Renata and Rogatko-Koroś, Marta and Mizia, Sylwia and Jaskuła, Emilia and Polak, Małgorzata and Mordak-Domagała, Monika and Lange, Janusz and Gronkowska, Anna and Jędrzejczak, Wiesław Wiktor and Kyrcz-Krzemień, Sławomira and Markiewicz, Mirosław and Dzierżak-Mietła, Monika and Tomaszewska, Agnieszka and Nasiłowska-Adamska, Barbara and Szczepiński, Andrzej and Hałaburda, Kazimierz and Hellmann, Andrzej and Czyż, Anna and Gil, Lidia and Komarnicki, Mieczysław and Wachowiak, Jacek and Barańska, Małgorzata and Kowalczyk, Jerzy and Drabko, Katarzyna and Goździk, Jolanta and Wysoczańska, Barbara and Bogunia-Kubik, Katarzyna and Graczyk-Pol, Elżbieta and Witkowska, Agnieszka and Marosz-Rudnicka, Anna and Nestorowicz, Klaudia and Dziopa, Joanna and Szlendak, Urszula and Warzocha, Krzysztof and Lange, Andrzej and Polish Donor-Recipient Matching St and Polish Donor-Recipient Matching Study Group
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 5, pp. 829 - 839
Abstract Some cancers treated with allogeneic hematopoietic stem cell transplantation (HSCT) are sensitive to natural killer cell (NK) reactivity. NK function... 
Hematology, Oncology and Palliative Medicine | Missing ligand | Activating killer cell immunoglobulin-like receptors | Bone marrow donor selection | Hematopoietic stem cell transplantation | Malignant diseases | Natural killer cell education | SURVIVAL | REPERTOIRE | NATURAL-KILLER-CELLS | RESPONSIVENESS | IMMUNOGLOBULIN-LIKE RECEPTORS | RECOGNITION | IMMUNOLOGY | TRANSPLANTATION | RELAPSE | MISSING SELF | LEUKEMIA | INCOMPATIBILITY | HEMATOLOGY | Hematologic Neoplasms - therapy | Receptors, KIR - genetics | Histocompatibility Testing | Humans | Middle Aged | Histocompatibility Antigens Class I - immunology | Child, Preschool | Hematopoietic Stem Cell Transplantation | Graft vs Tumor Effect - immunology | Infant | Male | Histocompatibility Antigens Class I - genetics | Killer Cells, Natural - pathology | Allografts | Adolescent | Killer Cells, Natural - immunology | Adult | Female | Unrelated Donors | Hematologic Neoplasms - genetics | Hematologic Neoplasms - immunology | Graft vs Tumor Effect - genetics | Child | Receptors, KIR - immunology | Killer cells | Transplantation | Hematopoietic stem cells | Stem cells | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study
by Jerzy Holowiecki and Sebastian Grosicki and Sebastian Giebel and Tadeusz Robak and Slawomira Kyrcz-Krzemien and Kazimierz Kuliczkowski and Aleksander B. Skotnicki and Andrzej Hellmann and Kazimierz Sulek and Anna Dmoszynska and Janusz Kloczko and Wieslaw W. Jedrzejczak and Barbara Zdziarska and Krzysztof Warzocha and Krystyna Zawilska and Mieczysław Komarnicki and Marek Kielbinski and Beata Piatkowska-Jakubas and Agnieszka Wierzbowska and Malgorzata Wach and Olga Haus
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 20, pp. 2441 - 2448
Purpose The goal of this study was to evaluate whether the addition of a purine analog, cladribine or fludarabine, to the standard induction regimen affects... 
CYTOSINE-ARABINOSIDE | THERAPY | PROGNOSTIC-FACTORS | FINAL REPORT | ONCOLOGY | ACUTE NONLYMPHOCYTIC LEUKEMIA | ACUTE MYELOGENOUS LEUKEMIA | LOW-DOSE CYTARABINE | COOPERATIVE GROUP | REMISSION INDUCTION | UNTREATED ADULT PATIENTS | Drug Administration Schedule | Humans | Middle Aged | Male | Vidarabine - analogs & derivatives | Remission Induction | Cytarabine - administration & dosage | Cladribine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Vidarabine - administration & dosage | Daunorubicin - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Acquired von Willebrand syndrome during systemic mastocytosis: An analysis of 21 cases
by Mital, Andrzej and Prejzner, Witold and Hellmann, Andrzej
Polish Archives of Internal Medicine, ISSN 0032-3772, 2018, Volume 128, Issue 7-8, pp. 491 - 493
MEDICINE, GENERAL & INTERNAL
Journal Article
Details down arrow
12. Full Text Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
by Cortes, Jorge E and Heidel, Florian H and Hellmann, Andrzej and Fiedler, Walter and Smith, B. Douglas and Robak, Tadeusz and Montesinos, Pau and Pollyea, Daniel A and DesJardins, Pierre and Ottmann, Oliver and Ma, Weidong Wendy and Shaik, M. Naveed and Laird, A. Douglas and Zeremski, Mirjana and O’Connell, Ashleigh and Chan, Geoffrey and Heuser, Michael
Leukemia, ISSN 0887-6924, 02/2019, Volume 33, Issue 2, pp. 379 - 389
Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of... 
AML | TRIAL | HEDGEHOG PATHWAY | MULTICENTER | OLDER PATIENTS | RESPONSE CRITERIA | ONCOLOGY | OPEN-LABEL | ARA-C | INHIBITOR | HEMATOLOGY | INTERNATIONAL WORKING GROUP | Dosage and administration | Genetic aspects | Cytarabine | Research | Myelodysplastic syndromes | Risk factors | Slopes | Pneumonia | Risk groups | Myeloid leukemia | Leukemia | Fatigue | Survival | Patients | Myelodysplastic syndrome | Confidence intervals | Chemotherapy | Randomization | Risk assessment | Remission | Acute myeloid leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
by Kreitman, Robert J and Dearden, Claire and Zinzani, Pier Luigi and Delgado, Julio and Karlin, Lionel and Robak, Tadeusz and Gladstone, Douglas E and le Coutre, Philipp and Dietrich, Sascha and Gotic, Mirjana and Larratt, Loree and Offner, Fritz and Schiller, Gary and Swords, Ronan and Bacon, Larry and Bocchia, Monica and Bouabdallah, Krimo and Breems, Dimitri A and Cortelezzi, Agostino and Dinner, Shira and Doubek, Michael and Gjertsen, Bjorn Tore and Gobbi, Marco and Hellmann, Andrzej and Lepretre, Stephane and Maloisel, Frederic and Ravandi, Farhad and Rousselot, Philippe and Rummel, Mathias and Siddiqi, Tanya and Tadmor, Tamar and Troussard, Xavier and Yi, Cecilia Arana and Saglio, Giuseppe and Roboz, Gail J and Balic, Kemal and Standifer, Nathan and He, Peng and Marshall, Shannon and Wilson, Wyndham and Pastan, Ira and Yao, Nai-Shun and Giles, Francis
Leukemia, ISSN 0887-6924, 08/2018, Volume 32, Issue 8, pp. 1768 - 1777
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B... 
DIAGNOSIS | EFFICACY | ONCOLOGY | RITUXIMAB | TERM-FOLLOW-UP | PATTERNS | ANTIBODY | ERADICATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CLADRIBINE | IMMUNOHISTOCHEMISTRY | Care and treatment | Cancer patients | Leukemia, Hairy cell | Genetic aspects | Research | Gene expression | Risk factors | Immunohistochemistry | Edema | Headache | Hemolytic uremic syndrome | Leukemia | Medical services | Minimal residual disease | Fatigue | Nausea | Malignancy | Males | Patients | CD22 antigen | Hairy cell leukemia | Lymphocytes B | Remission | Nucleoside analogs | Recombinant | Index Medicus | Life Sciences | Human health and pathology | Pharmacology | Hematology | Pharmaceutical sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials
by Bussel, James and Arnold, Donald M and Grossbard, Elliot and Mayer, Jiří and Treliński, Jacek and Homenda, Wojciech and Hellmann, Andrzej and Windyga, Jerzy and Sivcheva, Liliya and Khalafallah, Alhossain A and Zaja, Francesco and Cooper, Nichola and Markovtsov, Vadim and Zayed, Hany and Duliege, Anne‐Marie
American Journal of Hematology, ISSN 0361-8609, 07/2018, Volume 93, Issue 7, pp. 921 - 930
Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated platelet destruction in adults with immune thrombocytopenia (ITP).... 
RHEUMATOID-ARTHRITIS | SYK | EFFICACY | INADEQUATE RESPONSE | PURPURA | PHASE-III | DOUBLE-BLIND | TYROSINE KINASE INHIBITOR | ELTROMBOPAG | SPLENECTOMY | HEMATOLOGY | Pyridines - administration & dosage | Humans | Treatment Outcome | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Oxazines - adverse effects | Splenectomy | Pyridines - adverse effects | Platelet Count | Oxazines - therapeutic use | Syk Kinase - therapeutic use | Adult | Syk Kinase - administration & dosage | Oxazines - administration & dosage | Blood Platelets - drug effects | Chronic Disease | Pyridines - therapeutic use | Thrombocytopenia | Tyrosine | Clinical trials | Care and treatment | Product development | Adults
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights